913 related articles for article (PubMed ID: 22741814)
1. Clinical utility of neuroprotective agents in neurodegenerative diseases: current status of drug development for Alzheimer's, Parkinson's and Huntington's diseases, and amyotrophic lateral sclerosis.
Dunkel P; Chai CL; Sperlágh B; Huleatt PB; Mátyus P
Expert Opin Investig Drugs; 2012 Sep; 21(9):1267-308. PubMed ID: 22741814
[TBL] [Abstract][Full Text] [Related]
2. Advances in drug development for Parkinson's disease: present status.
Harikrishna Reddy D; Misra S; Medhi B
Pharmacology; 2014; 93(5-6):260-71. PubMed ID: 25096413
[TBL] [Abstract][Full Text] [Related]
3. The kynurenine pathway in neurodegenerative diseases: mechanistic and therapeutic considerations.
Tan L; Yu JT; Tan L
J Neurol Sci; 2012 Dec; 323(1-2):1-8. PubMed ID: 22939820
[TBL] [Abstract][Full Text] [Related]
4. Clinical potential of minocycline for neurodegenerative disorders.
Blum D; Chtarto A; Tenenbaum L; Brotchi J; Levivier M
Neurobiol Dis; 2004 Dec; 17(3):359-66. PubMed ID: 15571972
[TBL] [Abstract][Full Text] [Related]
5. [Clinical pharmacology and therapeutic aspects in certain degenerative neurological diseases].
Maloteaux JM
Bull Mem Acad R Med Belg; 1996; 151(10-11):429-32; discussion 432-4. PubMed ID: 9491620
[TBL] [Abstract][Full Text] [Related]
6. Oxidative stress in brain aging, neurodegenerative and vascular diseases: an overview.
Mariani E; Polidori MC; Cherubini A; Mecocci P
J Chromatogr B Analyt Technol Biomed Life Sci; 2005 Nov; 827(1):65-75. PubMed ID: 16183338
[TBL] [Abstract][Full Text] [Related]
7. Kaempferol, a potential neuroprotective agent in neurodegenerative diseases: From chemistry to medicine.
Jin S; Zhang L; Wang L
Biomed Pharmacother; 2023 Sep; 165():115215. PubMed ID: 37494786
[TBL] [Abstract][Full Text] [Related]
8. Potential of cystamine and cysteamine in the treatment of neurodegenerative diseases.
Gibrat C; Cicchetti F
Prog Neuropsychopharmacol Biol Psychiatry; 2011 Mar; 35(2):380-9. PubMed ID: 21111020
[TBL] [Abstract][Full Text] [Related]
9. Impacts of methylxanthines and adenosine receptors on neurodegeneration: human and experimental studies.
Chen JF; Chern Y
Handb Exp Pharmacol; 2011; (200):267-310. PubMed ID: 20859800
[TBL] [Abstract][Full Text] [Related]
10. Endocannabinoids and Neurodegenerative Disorders: Parkinson's Disease, Huntington's Chorea, Alzheimer's Disease, and Others.
Fernández-Ruiz J; Romero J; Ramos JA
Handb Exp Pharmacol; 2015; 231():233-59. PubMed ID: 26408163
[TBL] [Abstract][Full Text] [Related]
11. Tissue transglutaminase: a novel pharmacological target in preventing toxic protein aggregation in neurodegenerative diseases.
Wilhelmus MM; van Dam AM; Drukarch B
Eur J Pharmacol; 2008 May; 585(2-3):464-72. PubMed ID: 18417122
[TBL] [Abstract][Full Text] [Related]
12. Exploring the potential of natural and synthetic neuroprotective steroids against neurodegenerative disorders: A literature review.
Bansal R; Singh R
Med Res Rev; 2018 Jul; 38(4):1126-1158. PubMed ID: 28697282
[TBL] [Abstract][Full Text] [Related]
13. Nortriptyline delays disease onset in models of chronic neurodegeneration.
Wang H; Guan Y; Wang X; Smith K; Cormier K; Zhu S; Stavrovskaya IG; Huo C; Ferrante RJ; Kristal BS; Friedlander RM
Eur J Neurosci; 2007 Aug; 26(3):633-41. PubMed ID: 17686041
[TBL] [Abstract][Full Text] [Related]
14. Neural stem cell-based treatment for neurodegenerative diseases.
Kim SU; Lee HJ; Kim YB
Neuropathology; 2013 Oct; 33(5):491-504. PubMed ID: 23384285
[TBL] [Abstract][Full Text] [Related]
15. Benefits of curcumin in brain disorders.
Bhat A; Mahalakshmi AM; Ray B; Tuladhar S; Hediyal TA; Manthiannem E; Padamati J; Chandra R; Chidambaram SB; Sakharkar MK
Biofactors; 2019 Sep; 45(5):666-689. PubMed ID: 31185140
[TBL] [Abstract][Full Text] [Related]
16. PPARγ as a therapeutic target to rescue mitochondrial function in neurological disease.
Corona JC; Duchen MR
Free Radic Biol Med; 2016 Nov; 100():153-163. PubMed ID: 27352979
[TBL] [Abstract][Full Text] [Related]
17. Neuroprotection of Coenzyme Q10 in Neurodegenerative Diseases.
Yang X; Zhang Y; Xu H; Luo X; Yu J; Liu J; Chang RC
Curr Top Med Chem; 2016; 16(8):858-66. PubMed ID: 26311425
[TBL] [Abstract][Full Text] [Related]
18. Flavonoid-based therapies in the early management of neurodegenerative diseases.
Solanki I; Parihar P; Mansuri ML; Parihar MS
Adv Nutr; 2015 Jan; 6(1):64-72. PubMed ID: 25593144
[TBL] [Abstract][Full Text] [Related]
19. Modulating epigenetic HAT activity for reinstating acetylation homeostasis: A promising therapeutic strategy for neurological disorders.
Ganai SA; Banday S; Farooq Z; Altaf M
Pharmacol Ther; 2016 Oct; 166():106-22. PubMed ID: 27411674
[TBL] [Abstract][Full Text] [Related]
20. Rational drug discovery design approaches for treating Parkinson's disease.
Van der Schyf CJ
Expert Opin Drug Discov; 2015 Jul; 10(7):713-41. PubMed ID: 26054694
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
